Lung Cancer: Almonertinib vs. Chemotherapy

The study examined the efficacy and safety of almonertinib in combination with chemotherapy compared with monotertinib as second-line treatment for NSCLC.

In this study, we investigated the efficacy and safety of treatment with almonertinib in combination with chemotherapy compared with almonertinib monotherapy as second-line therapy for advanced non-small cell lung cancer (NSCLC) with a mutation in Epidermal Growth Factor Receptor (EGFR) gene.

The study included clinical information about 68 patients with advanced NSCLC who were treated at Jiangsu Provincial People’s Hospital and Nanjing Chest Hospital between April 2020 and December 2022. 30 patients of total received second-line treatment with a combination of almonertinib and platinum-based chemotherapy. And 38 patients were treated with only almontratinib (control group). The researchers also compared long-term and short-term outcomes and side effects between study groups.

The median follow-up duration ended December 31, 2022, at 16.3 months.

The log-rank test comparing the reserched groups showed that the median progression-free survival (mPFS) in reserched group was significantly longer than in control group by 3.1 months (12.7 vs 9.6 months; p = 0.01). The multivariate proportional hazards test for COX demonstrated a significant treatment benefit.

The researchers concluded that combination of almontrinib and chemotherapy was superior to almontrinib alone as second-line therapy for EGFR-mutated advanced NSCLC.

Source: https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1248690/full